Resultados de la búsqueda 31-40 of 14203 for chemoprevention

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This study aims to identify candidate High Grade Serous Cancer (HGSC) early detection and chemotherapy treatment response biomarkers. For the purpose of this ...

3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Create a registry of patients having or at risk for cancer of the liver or bile ducts (also known as hepatocellular carcinoma or cholangiocarcinoma), or ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This study aims to demonstrate acceptability and feasibility of the use of Distance Reiki therapy versus sham Reiki therapy among multiple myeloma patients.

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, ...

8. Hematología - Ensayos clínicos - Mayo Clinic

   This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The purposes of this study are to collect prostate surgical samples from metastatic patients to establish xenograft tumor lines for future testing of ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...